Nauck M. Incretin therapies-highlighting common features and differ- ences in the modes of action of GLP-1 receptor agonists and DPP-4 inhibitors. Diabetes Obes Metab. 2016;18:203-216.Nauck M (2015) Incretin therapies: highlighting common features and differences in the modes of action of ...
J. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr. Rev. 35, 992–1019 (2014). Article CAS PubMed Google Scholar Tella, S. H. & Rendell, M. S. Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a ...
GLP-1 enhances glucose-stimulated insulin release. GLP-1 agonists are resistant to degradation by DPP-4; thus these agonists are used clinically for the treatment of diabetes. DPP-4 inhibitors are also acceptable for use in diabetes patients because GLP-1 is rapidly deactivated by DPP-4. ...
As compared to treatment with DPP-4 inhibitors, the meal-induced plasma GLP-1 levels with elobixibat treatment are smaller [28]. However, it is important to point out that the meal stimulus in this study was a standardized low calorie chicken breast lunch, and that GLP-1 AUC measurements ...
In vitro experiments examined the molecular pathways through which EPZ compounds, protein arginine methyltransferase 5 (PRMT5) inhibitors, affect RANKL-induced osteoclast differentiation. The inhibitory impact of EPZ015866 on RANKL-stimulated osteoclast maturation surpassed that of EPZ015666. EPZ015866 ...
The GLP-1 receptor agonists class comprises seven compounds/preparations with a similar mode of action. • GLP-1 receptor agonists differ with respect to pharmacokinetic properties, duration of action, and clinical effectiveness. • Plasma glucose is lowered by effects on insulin and glucagon secre...
Proteins were extracted from cell or tissue samples using a protein lysis buffer supplemented with protease inhibitors (PMSF and cocktail). Western blot analysis was performed to detect the protein expression levels of Nogo-B, Nogo-A, Flag, GFP, proGCG, GLP1, PCSK1, GAPDH, and HSP90, follow...
In addition, GLP1RA counteracts the glucagon-raising effects of SGLT2 inhibitors via somatostatin release and SSTR2 signaling [46]. Thus, delta cell-regulation of alpha cells could constitute a potentially important route for the glucagonostatic effects of GLP1RA. Recent studies have also shown ...
GLP agonists, GLP receptor agonists, agonist of the GLP signal transduction cascade, compounds that stimulate the synthesis or expression of endogenous GLP, compounds that stimulate release of endogenous GLP, and compounds that inhibit inhibitors of GLP activity (i.e., an inhibitor of a GLP antagon...
Oren and Shai, 1998, “Mode of action of linear amphipathic alpha-helical antimicrobial peptides,” Biopolymers (Peptide Science), vol. 47, pp. 451-463. Patrias et al., 1994/1995,“Trimethylaminuria (Fish-malador syndrome) fnad the flavin monooxygenases”, Biotech Report, pp. 106-107. ...